NT-II™ Collagen for Joint Discomfort and Function
Hofseth Biocare ASA · NCT07119645
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 20–65 · All sexes
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Not applicable
- Target enrollment
- 120
- US sites recruiting
- 1
- Study start
- January 20, 2025
- Record last updated
- May 14, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The goal of this clinical trial is to learn whether a natural marine supplement called NT-II™ (Salmon Undenatured Type II Collagen) can help lower knee discomfort caused by physical activity in otherwise healthy adults. Many active people experience knee pain when performing daily movements like climbing stairs, walking long distances, or squatting, even if they do not have a medical diagnosis such as arthritis. This discomfort can limit mobility, impact exercise routines, and reduce overall quality of life. This study is being conducted to determine whether NT-II™, taken as a once-daily oral supplement, can reduce this type of activity-related knee discomfort more effectively than a commonly used joint supplement containing glucosamine and chondroitin.
The main questions the study aims to answer are:
Does NT-II™ reduce knee discomfort caused by repeated activity over a 12-week period?
Does NT-II™ improve movement and quality of life compared to glucosamine-chondroitin?
Researchers will compare two different doses of NT-II™ (240 mg and 480 mg) to glucosamine (1500 mg) plus chondroitin (1300 mg), which is used as an active comparator. All three products will be taken once daily for 12 weeks.
Participants will
Take their assigned supplement daily by mouth for 12 weeks
Track knee discomfort once per week using a pain rating scale called a visual analog scale (VAS) while doing an activity that usually causes discomfort, such as climbing stairs, walking, or squatting
Complete short surveys online about joint function, pain, and quality of life (including KOOS and SF-12 questionnaires)
Use a mobile app to perform simple knee range of motion tests at home
Wear a fitness tracker to monitor daily physical activity, such as step count and stair climbing
Collect two small blood samples at home using a finger-prick kit to check for changes in inflammation-related biomarkers
This study is for U.S.-based adults between the ages of 20 and 65 who are in generally good health but have had mild to moderate knee discomfort caused by physical activity for at least three months. The pain must be triggered by specific weight-bearing movements and be relieved by rest. Participants must not have osteoarthritis, rheumatoid arthritis, or other joint diseases. Individuals with recent knee injuries, major surgeries, or injections in the past six months cannot take part. Participants should not be using NSAIDs, turmeric, collagen, or other joint-related supplements during the study.
All study activities will take place remotely using a secure digital platform. There are no in-person clinic visits required. Eligible participants will receive all study materials by mail, including supplements, a wearable device, and an at-home blood sample collection kit. They will also be given access to a secure digital platform (Alethios) where they can complete questionnaires, enter pain ratings, and receive study instructions. Study staff will monitor progress, check for missing data, and assist participants through secure communication tools built into the platform.
The primary outcome of the study is the change in participant-reported knee discomfort, measured using a nominated activity VAS score (VASNA), from baseline to week 12. Additional outcomes will explore changes in function, mobility, physical activity, heart rate variability, and inflammatory biomarkers. The Pain Catastrophizing Scale (PCS) will also be used to examine whether thoughts and feelings about pain influence symptom reporting and treatment response.
This trial is sponsored by Hofseth BioCare ASA and is being conducted entirely online to improve access, lower participant burden, and support real-world understanding of joint health supplements. Study results may inform the use of NT-II™ as a marine-based nutritional strategy to support joint comfort in active individuals.
Being studied: NT-II™ (240 mg); NT-II™ 480 mg; Glucosamine/Chondroitin
Conditions: Activity-Related Knee Discomfort; Joint Discomfort; Functional Joint Pain; Functional Knee Pain; Knee Acute and Chronic Pain
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Adults aged 20 to 65 years.
- Self-reported, reproducible knee discomfort associated with any knee-loading activities for at least 3 months prior to screening.
- Discomfort must occur in at least one knee during a nominated aggravating activity at least twice per week and subside with rest.
- VAS rating of 30 mm to 75 mm during the past week for the nominated activity.
- No current diagnosis of structural joint disease (e.g., osteoarthritis).
- Engages in physical activity involving knee-loading movements at least twice weekly for 20+ minutes.
- BMI between 20.0 and 32.5 kg/m².
- In good general health with no significant medical comorbidities.
- Able and willing to provide informed consent.
- Capable of completing study procedures remotely using mobile technology.
Exclusion Criteria
- Persistent knee pain at rest or recent acute lower-limb trauma.
- Diagnosed structural or inflammatory joint disorders.
- Current or recent physiotherapy targeting knee pain (within 6 months).
- Allergy to fish or any study product ingredients.
- Scheduled lower-limb surgery during the study period.
- Other musculoskeletal disorders affecting ambulation.
- Recent joint injections (within 3 months).
- Use of joint supplements in the past 3 months.
- Use of analgesics ≥3 days/week in the past 3 months.
- NSAIDs/acetaminophen use is permitted with restrictions:
- Not within 24 hours of blood sampling or VAS assessments.
- Must be documented.
- Chronic use of medications that affect musculoskeletal symptoms (e.g., muscle relaxants, gabapentinoids) unless infrequent (≤2x/week) and not within 24 hours of assessments.
- Regular use of PPIs (>3x/week in past month).
- Systemic corticosteroids, immunosuppressants, or opioids within 4 weeks.
- Unstable weight or significant recent dietary changes.
- Significant medical conditions (e.g., cancer, hepatic/renal impairment, CVD, thyroid disease, diabetes).
- Neurological, cognitive, or psychiatric disorders affecting participation.
- Use of tobacco/nicotine or other substances.
- Diagnosed sleep disorders.
- Strict vegan diet or sedentary lifestyle.
- Inability to swallow capsules.
- Pregnant, breastfeeding, or planning pregnancy.
- Women of childbearing potential not using contraception.
- Participation in another interventional clinical trial.
Recruiting US locations
Alethios Inc.
San Francisco, CA 94109
Study contacts (from the official record)
- Crawford Head of Medical R&D, MD · +44 7968195497 · cc@hofsethbiocare.no
- Christian Medical Advisor, MD · +47 967 12 226 · chbj@hofsethbiocare.no
Similar studies in California
All pain studies in California →- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
Phase 1 Study of SBS-147 in Healthy Adults
Sparian Biosciences, Inc
- Location
- Cypress, CA
- Eligibility basics
- Ages 18–55
- RecruitingHealthy volunteersEarly Phase 1
Brain Mechanisms Supporting Cannabis-induced Pain Relief
University of California, San Diego
- Location
- La Jolla, CA
- Eligibility basics
- Ages 21–65
- RecruitingPhase 3
An Open-Label, Safety and Efficacy Study of Cebranopadol in Participants With Acute Pain With Surgical or Non-Surgical Origin
Adneuris Therapeutics, Inc.
- Location
- Riverside, CA + 14 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
Efficacy and Safety of VER-01 in the Treatment of Participants With Chronic Painful Lumbosacral Radiculopathy
Vertanical GmbH
- Location
- Long Beach, CA + 22 other US sites
- Eligibility basics
- Ages 18+